Biogen Inc.
IDP.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$32.49B
Close$
Share Statistics
| Market cap | $32.49 Billion |
|---|---|
| Enterprise Value | $39.65 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 4.43% |
|---|---|
| Return on Assets | 2.60% |
| Return on Invested Capital | 4.02% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.95 |
| Enterprise Value to EBIT | 35.02 |
| Enterprise Value to Net Income | 47 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$2.74
Average shareholder expectationRevenue Estimate
$2.09 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...